Skin Study Center

The Skin Study Center in the Department of Dermatology is a translational research facility dedicated toward advancing our understanding about various skin diseases and skin health. The unit serves as a facility for human volunteers who are participating in basic or clinical research studies. Located in 512 Wearn within University Hospitals, the Skin Study Center plays a pivotal role in various investigative research projects pertaining to immunology, photobiology, and various skin and hair diseases (e.g. psoriasis, atopic dermatitis, contact dermatitis, alopecia areata, skin cancers). The facility houses a 1000-Watt solar simulator, skin ultrasound machine, transepidermal water loss unit (TEWL), chromometer, digital cameras, other UV sources and UV meters, motorized AESCULAP keratome device for horizontal skin biopsies, and micrometer for measurement of skin thickness.

As a translational core facility affiliated with both Case Western Reserve University and University Hospitals of Cleveland, we are unique in that we provide support and resources for our own team of nationally renowned researchers in addition to other departmental and industry-sponsored clinical research studies. We work closely with the NIH-funded General Clinical Research Center and National Cancer Institute-designated Case Comprehensive Cancer Center/Ireland Cancer Center.

Currently, we are conducting various studies focused on psoriasis, atopic dermatitis, skin cancers, lymphoma, and tests on new and future sun protection creams and products.

 

Current Studies
  1. A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa (Abbott M12-555)
     
  2. A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis:  AMAGINE-3
     
  3. A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
     
  4. A PHASE 3B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOUBLE-DUMMY, STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004), ETANERCEPT, AND PLACEBO, IN SUBJECTS WITH MODERATE TO A PHASE 3B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOUBLE-DUMMY, STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004), ETANERCEPT, AND PLACEBO, IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
     
  5. A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
     
  6. Kyowa Hakko Kirin Pharma, Inc. / “Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma”
     
  7. A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate to-Severe Plaque Psoriasis
     
  8. A 52-Week, Phase 3, Randomized, , Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)
     
  9. A Randomized, Double-Blind, Placebo Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab
     
  10. A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITOR
     
  11. A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE
     
  12. Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
     
  13. A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
     
  14. A Randomized, Double-Blind, Placebo Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
     
  15. PROVE: A PROspective, observational, US-based study assessing outcomes, adverse events, treatment patterns, and quality of life in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma and treated with Valchlor
     
  16. I1F-MC-RHBP: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
     
  17. Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris
     
  18. Post-Approval Study of MelaFind 
     
  19. A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
     
  20. Evaluation of Cardiovascular Risk Profile in Psoriasis Patients by the Use of Pro-inflammatory Markers in Skin and Cardiovascular Disease
     
  21. Sleep, Circadian Rhythm and Skin Health
     
  22. Effect of Etanercept on UV-induced contact sensitivity suppression in psoriasis patients
     
  23. Effect of ACCS in UV-induced inflammation

(216) 844-SKIN (7546) for more information.


Back to top